Movement Alert｜Innovent Biologics Rises 3.46% in Regular Trading, New Drug Pikanqibai Approved Amid Biotech Sector Recovery

Market Focus

05/21

On May 21, Innovent Biologics rose 3.46% in regular trading, trading at HKD 81.6/share, with trading volume of HKD 182 million.

On the news front, Innovent Biologics announced on May 20 that its independently developed Pikanqibai injection (Xinmeiyue) received NMPA approval for the treatment of moderate-to-severe plaque psoriasis in adult patients. The product is an innovative antibody that specifically binds to the IL-23 p19 subunit, with multiple clinical studies having achieved their endpoints. The new drug approval is expected to further enrich the company's non-oncology product pipeline.

Additionally, the broader biotech sector saw a recovery, with AKESO up 6.26%, Remegen up 2.97%, SKB Bio up 3.80%, and BeiGene up 2.38%. The improved sector sentiment provided support for Innovent Biologics' rebound following its previous consecutive pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1192913617"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192913617\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192913617?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192913617","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.46% in Regular Trading, New Drug Pikanqibai Approved Amid Biotech Sector Recovery","media":"Market Focus","content":"<p><p>On May 21, Innovent Biologics rose 3.46% in regular trading, trading at HKD 81.6/share, with trading volume of HKD 182 million.</p><p>On the news front, Innovent Biologics announced on May 20 that its independently developed Pikanqibai injection (Xinmeiyue) received NMPA approval for the treatment of moderate-to-severe plaque psoriasis in adult patients. The product is an innovative antibody that specifically binds to the IL-23 p19 subunit, with multiple clinical studies having achieved their endpoints. The new drug approval is expected to further enrich the company's non-oncology product pipeline.</p><p>Additionally, the broader biotech sector saw a recovery, with AKESO up 6.26%, Remegen up 2.97%, SKB Bio up 3.80%, and BeiGene up 2.38%. The improved sector sentiment provided support for Innovent Biologics' rebound following its previous consecutive pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.46% in Regular Trading, New Drug Pikanqibai Approved Amid Biotech Sector Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.46% in Regular Trading, New Drug Pikanqibai Approved Amid Biotech Sector Recovery\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-05-21 09:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On May 21, Innovent Biologics rose 3.46% in regular trading, trading at HKD 81.6/share, with trading volume of HKD 182 million.</p><p>On the news front, Innovent Biologics announced on May 20 that its independently developed Pikanqibai injection (Xinmeiyue) received NMPA approval for the treatment of moderate-to-severe plaque psoriasis in adult patients. The product is an innovative antibody that specifically binds to the IL-23 p19 subunit, with multiple clinical studies having achieved their endpoints. The new drug approval is expected to further enrich the company's non-oncology product pipeline.</p><p>Additionally, the broader biotech sector saw a recovery, with AKESO up 6.26%, Remegen up 2.97%, SKB Bio up 3.80%, and BeiGene up 2.38%. The improved sector sentiment provided support for Innovent Biologics' rebound following its previous consecutive pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信達生物","start_time":0,"source_url":"","article_id":"1192913617","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192913617","pubTimestamp":1779328716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, Innovent Biologics rose 3.46% in regular trading, trading at HKD 81.6/share, with trading volume of HKD 182 million.On the news front, Innovent Biologics announced on May 20 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动感快讯|信达生物常规盘涨3.46%新药皮坎奇柏获批生技板块回暖","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On May 21, Innovent Biologics rose 3.46% in regular trading, trading at HKD 81.6/share, with trading volume of HKD 182 million.On the news front, Innovent Biologics announced on May 20 that its independently developed Pikanqibai injection (Xinmeiyue) received NMPA approval for the treatment of moderate-to-severe plaque psoriasis in adult patients. The product is an innovative antibody that specifically binds to the IL-23 p19 subunit, with multiple clinical studies having achieved their endpoints. The new drug approval is expected to further enrich the company's non-oncology product pipeline.Additionally, the broader biotech sector saw a recovery, with AKESO up 6.26%, Remegen up 2.97%, SKB Bio up 3.80%, and BeiGene up 2.38%. The improved sector sentiment provided support for Innovent Biologics' rebound following its previous consecutive pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}